Enliven appoints Biopharma exec to Board ahead of Phase 3 relcobatinib trial
Enliven Therapeutics announced the appointment of Kristine Ball to its Board of Directors to help prepare for a pivotal Phase 3 trial of relcobatinib and future commercialization, reflecting a focus on its late-stage pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed